Skip to search formSkip to main contentSkip to account menu

GFT505

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH
2016
2016
Preparation and intermediates Gft505
The present invention discloses a method for preparing GFT505 and intermediates thereof. The present invention provides a method… 
Review
2014
Review
2014
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Introduction: PPARs are nuclear receptors that play key roles in the regulation of metabolism and inflammation. GFT505 is a new… 
2013
2013
O45 Le GFT505, un co-agoniste PPARα/δ, améliore la sensibilité périphérique et hépatique à l’insuline chez des patients obèses insulinorésistants
2012
2012
1410 A RANDOMIZED, CONTROLLED, MULTICENTRE TRIAL COMPARING ENDOSCOPIC BAND LIGATION VERSUS TIPS IN CIRRHOTIC PATIENTS WITH RECURRENT VARICEAL BLEEDING NON-RESPONDING TO PHARMACOLOGICAL THERAPY
2012
2012
1409 THE NEW DUAL PPARα/δ AGONIST GFT505 IMPROVES HEPATIC INSULIN RESISTANCE AND DECREASES SERUM LIVER ENZYMES IN ABDOMINALLY OBESE PATIENTS
2011
2011
Effects of the NewDual PPAR a / d Agonist GFT 505 on Lipid and Glucose Homeostasis in Abdominally Obese PatientsWith Combined Dyslipidemia or Impaired GlucoseMetabolism
RESEARCH DESIGN AND METHODSdThe S1 study was conducted in 94 patients with combined dyslipidemia while the S2 study was conducted… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)